Safety and Efficacy of PB-119 in Subjects With Type 2 Diabetes and Not Well-controlled by Metformin Monotherapy
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 620 participants.
Also called NCT04504396
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 620 participants
- Sponsor
- Registry
-
NCT04504396
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT04504396. Randomized; quadruple masking; primary purpose treatment. Start 2020-06-23 (actual); primary completion 2022-09-15 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Safety and Efficacy of PB-119 in Subjects With Type 2 Diabetes and Not Well-controlled by Metformin Monotherapy
- Condition
- Type 2 Diabetes Mellitus (T2DM)
- Intervention (Drug)
- GLP-1 receptor agonist
- Intervention (Drug)
- Placebo
- Lead sponsor
- PegBio Co., Ltd.
Record details
- Record id
cardio:ct-nct04504396- Content hash
6e583262cd5fcaa1991a9d162c099964c2f6b42c85477650144f93bdf07b6420